Prospective evaluation of soluble CD14 as a biomarker following five aflibercept treatments in diabetic macular edema
Abstract Using spectral-domain optical coherence tomography (SD-OCT) in patients with diabetic macular edema (DME), we studied the relationships between consecutive aflibercept treatments, soluble CD14 (sCD14) in the aqueous humor (AH), and anatomical features, including hyper-reflective foci (HFs)...
Saved in:
| Main Authors: | Hyungwoo Lee, Minsub Lee, Najung Kim, Nahee Kim, Dayoung Moon, Chanok Son, Hyewon Chung |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-05-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-025-93472-w |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comparisons of One to Three Monthly Injections of Aflibercept for Diabetic Macular Edema by Practical Protocol
by: Yuko Hayashi, et al.
Published: (2021-01-01) -
Comparison of the Efficacy of Intravitreal Aflibercept and Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion
by: Jia-Kang Wang, et al.
Published: (2016-01-01) -
Effect of Faricimab versus Aflibercept on Hyperreflective Foci in Patients with Diabetic Macular Edema from the YOSEMITE/RHINE Trials
by: Usha Chakravarthy, FRCOphth, PhD, et al.
Published: (2025-09-01) -
Transitioning from Aflibercept to Biosimilar Ranibizumab in Diabetic Macular Edema (DME): (The TRANSFORM-DME Trial) a Multicenter Observational Study
by: Chakraborty D, et al.
Published: (2024-11-01) -
Changes of retinal ganglion cell–inner plexiform layer thickness and visual acuity in patients with diabetic macular edema treated with Aflibercept
by: Mouna M. Alsaad, et al.
Published: (2025-01-01)